Preferred Label : Rilpivirine;
MeSH definition : A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity
against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in
combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly
when it is used alone.;
MeSH hyponym : Rilpivirine Hydrochloride; R278474; TMC 278; Hydrochloride, Rilpivirine; Rilpivirine HCl; HCl, Rilpivirine; 278, TMC; TMC278; TMC-278;
MeSH Related Number : 212WAX8KDD; 500287-72-9;
Wikipedia link : https://en.wikipedia.org/wiki/Rilpivirine;
Is substance : O;
UNII : FI96A8X663;
Origin ID : D000068696;
UMLS CUI : C1566826;
ATC code(s)
ATC code(s)
Allowable qualifiers
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity
against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in
combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly
when it is used alone.
https://www.has-sante.fr/jcms/p_3601303/fr/edurant-rilpivirine-vih
2025
false
false
false
France
child
adult
evaluation of the transparency committee
human immunodeficiency virus, nos
Rilpivirine
hiv infections
---
https://www.has-sante.fr/jcms/p_3412895/fr/rekambys-rilpivirine-vih
2023
false
false
false
France
injections, intramuscular
hiv infections
HIV-1
anti-hiv agents
rilpivirine
drug therapy, combination
reverse transcriptase inhibitors
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
Rilpivirine
---
Rekambys - rilpivirine
https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
2021
false
false
false
Netherlands
French
English
Rilpivirine
Rilpivirine
drug approval
europe
treatment outcome
package leaflet
summary of product characteristics
drug evaluation
syndication feed
rilpivirine
hiv infections
anti-hiv agents
anti-hiv agents
reverse transcriptase inhibitors
reverse transcriptase inhibitors
Delayed-Action preparations
drug therapy, combination
HIV-1
cabotegravir
adult
injections, intramuscular
Non-nucleoside Reverse Transcriptase Inhibitor
Non-nucleoside Reverse Transcriptase Inhibitor
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely rilpivirine 300 milligram/1 milliliter prolonged-release
suspension for injection (clinical drug)
cabotegravir
pyridones
---
https://www.has-sante.fr/jcms/p_3263060/fr/rekambys-rilpivirine
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
anti-hiv agents
reverse transcriptase inhibitors
rilpivirine
Delayed-Action preparations
injections, intramuscular
guidelines for drug use
drug therapy, combination
cabotegravir
adult
HIV-1
hiv infections
evaluation of the transparency committee
Rilpivirine
cabotegravir
pyridones
---
TIVICAY, TRIUMEQ and JULUCA (dolutegravir containing medicines) – Possible Risk of
Neural Tube Defects
Destinataires : Professionnels de la santé, y compris spécialistes des maladies infectieuses,
spécialistes du virus de l’immunodéficience humaine (VIH) et infirmiers(ères), virologues
cliniques, obstétriciens(ennes), gynécologues, pédiatres, spécialistes de la santé
sexuelle, pharmaciens(ennes) et omnipraticiens(ennes).
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66998a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
guidelines for drug use
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
Abacavir/Dolutegravir/Lamivudine
Rilpivirine
---
https://www.ema.europa.eu/medicines/human/EPAR/Juluca
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Rilpivirine
dolutegravir
drug combinations
dolutegravir and rilpivirine
drug approval
europe
treatment outcome
HIV integrase inhibitors
HIV integrase inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
dolutegravir, rilpivirine drug combination
---
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca-dolutegravir/rilpivirine-association-d-antiviraux
2018
false
false
false
France
French
drug combinations
dolutegravir and rilpivirine
treatment outcome
HIV integrase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
evaluation of the transparency committee
guidelines for drug use
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
---
https://www.ema.europa.eu/medicines/human/EPAR/Odefsey
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
emtricitabine, tenofovir alafenamide and rilpivirine
drug approval
europe
treatment outcome
Emtricitabine
Rilpivirine
tenofovir alafenamide
tenofovir alafenamide
drug combinations
product surveillance, postmarketing
adult
adolescent
hiv infections
HIV-1
human immunodeficiency virus i infection
administration, oral
reverse transcriptase inhibitors
reverse transcriptase inhibitors
anti-hiv agents
anti-hiv agents
prodrugs
risk assessment
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Rilpivirine Hydrochloride
Rilpivirine Hydrochloride
tenofovir alafenamide
Tenofovir
Emtricitabine
Rilpivirine
tenofovir alafenamide
adenine
---
http://www.has-sante.fr/portail/jcms/c_2732128/fr/odefsey
http://www.has-sante.fr/portail/jcms/c_2732128/fr/odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-association-d-antiretroviraux
2016
false
false
false
France
French
evaluation of the transparency committee
tenofovir alafenamide
tenofovir alafenamide
guidelines for drug use
administration, oral
treatment outcome
insurance, health, reimbursement
reverse transcriptase inhibitors
reverse transcriptase inhibitors
anti-hiv agents
anti-hiv agents
hiv infections
emtricitabine, tenofovir alafenamide and rilpivirine
adult
adolescent
human immunodeficiency virus i infection
HIV-1
Emtricitabine
Emtricitabine
Rilpivirine Hydrochloride
Rilpivirine Hydrochloride
tenofovir alafenamide
tenofovir alafenamide
adenine
adenine
adenine
Rilpivirine
Rilpivirine
---
https://www.ema.europa.eu/medicines/human/EPAR/Edurant
2012
false
United Kingdom
English
French
drug evaluation
package leaflet
summary of product characteristics
syndication feed
Rilpivirine
Rilpivirine
drug approval
treatment outcome
hiv infections
HIV reverse transcriptase
reverse transcriptase inhibitors
reverse transcriptase inhibitors
administration, oral
drug therapy, combination
HIV-1
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
rilpivirine
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/edurant-1423.html
2012
false
Canada
English
French
Rilpivirine
evaluation of the transparency committee
administration, oral
hiv infections
HIV reverse transcriptase
rilpivirine
treatment outcome
Cost-Benefit analysis
reverse transcriptase inhibitors
drug therapy, combination
HIV-1
adult
clinical trials, phase iii as topic
drug evaluation
---
http://www.has-sante.fr/portail/jcms/c_1250134/edurant
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-05/edurant_09052012_avis_ct11993.pdf
2012
false
France
French
evaluation of the transparency committee
Rilpivirine
Rilpivirine
administration, oral
insurance, health, reimbursement
rilpivirine
HIV reverse transcriptase
adult
drug therapy, combination
hiv infections
HIV-1
aged
treatment outcome
clinical trials, phase iii as topic
anti-hiv agents
anti-hiv agents
reverse transcriptase inhibitors
reverse transcriptase inhibitors
---
http://www.meddispar.fr/Medicaments/EDURANT-25-FL-30/(type)/letter/(value)/E/(cip)/3400921947298
2012
false
France
French
Rilpivirine
drug information
administration, oral
drug prescriptions
legislation, drug
rilpivirine
anti-hiv agents
---
http://www.has-sante.fr/portail/jcms/c_1329982/edurant-rilpivirine-inhibiteur-non-nucleosidique-de-la-transcriptase-inverse
http://www.has-sante.fr/portail/jcms/c_1329962/edurant-09052012-synthese
http://www.has-sante.fr/portail/jcms/c_1250741/edurant-09052012-avis-ct11993
2012
false
France
French
Rilpivirine
Rilpivirine
administration, oral
HIV-1
anti-hiv agents
anti-hiv agents
rilpivirine
insurance, health, reimbursement
adult
HIV reverse transcriptase
clinical trials, phase iii as topic
treatment outcome
drug therapy, combination
guidelines for drug use
evaluation of the transparency committee
reverse transcriptase inhibitors
reverse transcriptase inhibitors
---
Summary Basis of Decision (SBD) for EDURANT - Rilpivirine hydrochloride, 25 mg tablet
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00046
2011
false
Canada
French
English
Rilpivirine
Rilpivirine
HIV reverse transcriptase
administration, oral
rilpivirine
reverse transcriptase inhibitors
reverse transcriptase inhibitors
drug approval
treatment outcome
risk assessment
drug therapy, combination
HIV-1
hiv infections
adult
clinical trials, phase iii as topic
randomized controlled trials as topic
drug evaluation
---